

Number ID: **76704**

Publication Name: **World Journal of Gastrointestinal Oncology/ Transferred to the World Journal of Gastrointestinal Pathophysiology**

Author: Violeta Snegarova\*, Dimitrina Miteva\*, Milena Gulinac, Monika Peshevska-Sekulovska, Hristiana Batselova, Tsvetelina Velikova

\*Both authors contributed equally to the paper and have to be listed as co-first authors.

Title: COVID-19 in patients with gastrointestinal stromal tumors: recommendations for managing and vaccination

Running title: COVID-19 and GIST

Please resolve all issues in the manuscript based on the peer review report and make a point-by-point response to each of the issues raised in the peer review report. Note, authors must resolve all issues in the manuscript that are raised in the peer-review report(s) and provide point-by-point responses to each of the issues raised in the peer-review report(s); these are listed below for your convenience:

Dear Editor,

Dear reviewers,

Thank you for your time to review our Manuscript ID: 76704, Violeta Snegarova\*, Dimitrina Miteva\*, Milena Gulinac, Monika Peshevska-Sekulovska, Hristiana Batselova, Tsvetelina Velikova, entitled COVID-19 in patients with gastrointestinal stromal tumors: recommendations for managing and vaccination submitted for consideration in World Journal of Pathophysiology. We have incorporated most of the suggestions made by the reviewers. Those changes are made visible by using track changes within the manuscript. Please see below, in blue, for a point-by-point response to the reviewers' comments. All page numbers refer to the revised manuscript file.

Reviewer #1:

Scientific Quality: Grade B (Very good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Minor revision

Specific Comments to Authors: Suggestions:

1. This paper is a very good minireview, it provides a reference for the vaccination of the clinical GIST patients in the new coronal period.

- Thank you very much for the overall good evaluation of our paper. We took seriously all of the comments and suggestions made to improve our paper.

2. In this minireview, the authors mentioned several common coronavirus vaccines, including mRNA vaccine、 adenoviral vector vaccine、 CoronaVac vaccine、 BBIBP-CorV vaccine and etc, are there any recommended types of coronavirus vaccine for GIST patients in the current guidelines?

- Thank you for the good question. Unfortunately, up to date, there are no official recommendations specially for GIST. Based on this, we used and extrapolate the vaccine recommendations for gastroenterology and oncology. We stated this in the beginning of the section entitled “OFFICIAL RECOMMENDATIONS FOR COVID-19 VACCINATION IN PATIENTS WITH GIST”.

3. The diagnosis and treatment progress and pathological characteristics of GIST need to be further refined.

- We agree with the referee that this point is substantial, therefore, we aimed a whole section of the paper entitled “GIST - PATHOLOGICAL POINT OF VIEW”.

Reviewer #2:

Scientific Quality: Grade C (Good)

Language Quality: Grade C (A great deal of language polishing)

Conclusion: Major revision

Specific Comments to Authors:

This study is good, but authors failed to justify inclusion and exclusion criteria. PRISMA checklist must be followed.

- Thank you for the valuable comment. We agree that the inclusion and exclusion criteria are not mentioned. We add a paragraph on our search strategy. However, we did not perform a systematic review and PRISMA is not applicable for our paper.

There is no graphical representation of this topic.

- We have a table as illustrative material for our paper. If the referee and the editors insist, we can craft a drawing for the manuscript.

The English language is also need polishing there are multiple grammatical, syntax and punctuation issues. Generally, there is no novelty in this work, stated adverse symptoms are already reported in general population with no GIST.

- Our manuscript was revised by a colleague, who is native in English and French. We agree with the referee, that the adverse effects are similar in GIST patients and other GI patients. However, these are the results published so far. The novelty of our paper is gathering all the information that existed in the field. There are no such papers published so far.

#### 4 LANGUAGE POLISHING REQUIREMENTS FOR REVISED MANUSCRIPTS SUBMITTED BY AUTHORS WHO ARE NON-NATIVE SPEAKERS OF ENGLISH

As the revision process results in changes to the content of the manuscript, language problems may exist in the revised manuscript. Thus, it is necessary to perform further language polishing that will ensure all grammatical, syntactical, formatting and other related errors be resolved, so that the revised manuscript will meet the publication requirement (Grade A).

- Our manuscript was revised by a colleague, who is native in English and French

#### 6 EDITORIAL OFFICE'S COMMENTS

Authors must revise the manuscript according to the Editorial Office's comments and suggestions, which are listed below:

(1) Science editor:

This is a mini-review on managing COVID-19 in patients with gastrointestinal stromal tumors. The topic is of interest, however, it lacks novelty, authors should include more studies with a stringent inclusion and exclusion criteria to justify the hypothesis. Finally, the English language is unacceptable in its present form.

Language Quality: Grade C (A great deal of language polishing)

Scientific Quality: Grade E (Do not publish)

➤ Our manuscript was revised by a colleague, who is native in English and French

(2) Company editor-in-chief:

I recommend the manuscript to be published in the World Journal of Gastrointestinal Pathophysiology.

➤ Thank you for the comments. We agree with the editors` decision and suggestions.